ArticleJournal of neurogastroenterology and motility2016
Granisetron Transdermal System for Treatment of Symptoms of Gastroparesis: A Prescription Registry Study.
Article in Journal of neurogastroenterology and motility, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Gastroenterological Society of Australia Position Statement on the Assessment and Management of Idiopathic Gastroparesis.Journal of gastroenterology and hepatology · 2026Guideline
- European Guideline on Chronic Nausea and Vomiting-A UEG and ESNM Consensus for Clinical Management.United European gastroenterology journal · 2025Guideline
- The Role of GI Peptides in Functional Dyspepsia and Gastroparesis: A Systematic Review.Frontiers in psychiatry · 2020Pooled it
- Granisetron transdermal delivery system versus palonosetron in the prevention of long-delayed nausea and vomiting: a phase III randomized trial.The oncologist · 2026Trial
- Effects of ondansetron on symptoms during a gastric emptying study and enteral lipid challenge and on daily symptoms in diabetic gastroenteropathy.Neurogastroenterology and motility · 2024Trial
- Prolonged administration of the granisetron transdermal delivery system reduces capecitabine plus oxaliplatin regimen induced nausea and vomiting.BMC cancer · 2024Trial
- Pharmacologic treatments for gastroparesis.Pharmacological reviews · 2025Review
- Imaging in Gastroparesis: Exploring Innovative Diagnostic Approaches, Symptoms, and Treatment.Life (Basel, Switzerland) · 2023Review
- Gastroparesis: Myths, Misconceptions, and Management.Clinical and experimental gastroenterology · 2023Review
- A New Paradigm Shift in Gastroparesis Management.Gut and liver · 2022Review
- Gastroparesis.Gastroenterology · 2022Review
- Management of Gastroparesis.Gastroenterology & hepatology · 2021Article
- EndoFLIP and Pyloric Dilation for Gastroparesis Symptoms Refractory to Pyloromyotomy/Pyloroplasty.Digestive diseases and sciences · 2021Article
- Efficient Synthesis of a New Family of 2,6-Disulfanyl-9-selenabicyclo[3.3.1]nonanes.Molecules (Basel, Switzerland) · 2021Article
- United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis.United European gastroenterology journal · 2021Article
- Gastroparesis in the 2020s: New Treatments, New Paradigms.Current gastroenterology reports · 2020Review
- Diabetic gastroparesis: current challenges and future prospects.Clinical and experimental gastroenterology · 2018Review
- A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research.Frontiers in pharmacology · 2018Review
- Diabetes and the Stomach.Current treatment options in gastroenterology · 2017Review
- Gastroparesis: Medical and Therapeutic Advances.Digestive diseases and sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsSerotonin receptor (eg, 5-HT₃) antagonists are used to treat nausea and vomiting from a variety of causes. Granisetron transdermal system (GTS) is an appealing delivery system for patients with gastroparesis. To assess if GTS improves nausea and vomiting and other gastroparesis symptoms in patients with gastroparesis.
methodsPatients with gastroparesis and symptoms of nausea and vomiting refractory to conventional treatment were treated with GTS. Symptoms of gastroparesis were assessed using a modified Gastroparesis Cardinal Symptom Index (GCSI). Following 2 weeks of treatment, patients were asked to assess their symptoms and indicate their therapeutic response using the Clinical Patient Grading Assessment Scale (CPGAS) reporting if symptoms of nausea and vomiting improved on a scale: 0 = no change to +7 = completely better.
resultsFifty-one patients received GTS by prescription: average age was 40 ± 17 years, 44 female, 11 diabetics, 23 ± 20% retention at 4 hours on gastric emptying scintigraphy. Thirty-nine of the 51 (76%) patients stated improvement with GTS. There was significant improvement in nausea and vomiting as assessed with CPGAS at 2 weeks (2.28 ± 2.53;
conclusionsGTS was moderately effective in reducing nausea and/or vomiting in 76% of gastroparesis patients. In addition to nausea and vomiting, symptoms of postprandial fullness, loss of appetite, upper abdominal pain, and early satiety also improved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.